Utah Medicaid spending on GLP-1 drugs

How much did Utah Medicaid spend on GLP-1 drugs like Ozempic and Mounjaro in 2025?

Pharmacies were reimbursed at least $28.6 million for GLP-1 drugs paid through Utah Medicaid in 2025, across at least 28,007 prescriptions, according to CMS’s State Drug Utilization Data. That is the total amount reimbursed, federal and state shares together, before the rebates manufacturers pay states. CMS suppressed 97 rows of 247, so these figures are floors.

Pharmacies were reimbursed at least $7.8 million for GLP-1 drugs paid through Utah Medicaid in 2026 (quarter 1 only, as posted so far), across at least 7,689 prescriptions, according to CMS’s State Drug Utilization Data. That is the total amount reimbursed, federal and state shares together, before the rebates manufacturers pay states. CMS suppressed 34 rows of 79, so these figures are floors.

By year and ingredient

2020at least $705,326No data$2,552,937at least $2,803,772at least $724,381No dataat least $118,216Suppressedat least $6,904,632
2021at least $2,027,257No data$1,954,581at least $6,613,907at least $499,821Suppressedat least $198,688Suppressedat least $11,294,253
2022at least $3,636,724at least $15,309at least $1,504,182at least $9,984,934at least $343,284Suppressedat least $221,382Suppressedat least $15,705,815
2023at least $5,567,226at least $799,327$833,953at least $10,677,754at least $135,377No dataat least $128,314Suppressedat least $18,141,952
2024at least $9,518,814at least $3,862,176at least $467,085at least $8,353,306at least $113,821No dataat least $94,225Suppressedat least $22,409,428
2025at least $10,739,782at least $9,091,103at least $250,938at least $8,407,745at least $46,573No dataat least $112,809Suppressedat least $28,648,950
2026 (Q1)at least $4,194,848at least $1,597,446at least $40,341at least $1,942,670No dataNo data$13,352No dataat least $7,788,657

By product, 2025

Ozempic$9,941,3029,6170 of 24
Rybelsusat least $731,773at least 7009 of 21
Wegovyat least $66,707at least 4926 of 30
Mounjaroat least $9,008,965at least 8,3771 of 49
Zepboundat least $82,138at least 7821 of 26
Liraglutide (generic name listing)at least $175,698at least 37616 of 33
SaxendaSuppressedSuppressed1 of 1
Victozaat least $75,240at least 9910 of 12
Trulicityat least $8,407,745at least 8,4966 of 38
Bydureon$46,573580 of 2
ByettaSuppressedSuppressed2 of 2
Soliquaat least $112,809at least 1571 of 5
XultophySuppressedSuppressed4 of 4

By quarter, 2025

Q1 2025at least $6,639,190at least 6,56217 of 54
Q2 2025at least $7,022,324at least 6,84622 of 58
Q3 2025at least $7,209,361at least 6,98532 of 66
Q4 2025at least $7,778,075at least 7,61426 of 69

By quarter, 2026 (posted so far)

Q1 2026at least $7,788,657at least 7,68934 of 79

The amounts are CMS’s “Total Amount Reimbursed” field. CMS’s data dictionary for State Drug Utilization Data says of it:

“This total is not reduced or affected by Medicaid rebates paid to the state. This amount represents both the Federal and State Reimbursement and is inclusive of dispensing fees.”

Its prescription count is “The number of prescriptions reimbursed (by the Medicaid Program ONLY) to pharmacists for the (11-digit NDC) drug for the period covered.”

CMS suppresses some rows (its “Suppression Used” field is true and the counts and amounts are left blank). Here a suppressed row is never counted as zero: a figure that includes suppressed rows is shown as “at least” the sum of the rows CMS did publish, and a figure where every row is suppressed is shown as “Suppressed.” The “Rows suppressed” column gives the count. Where many rows are suppressed, the published sum can be well below the full amount, so floors for different states are not directly comparable.

Fee-for-service and managed care rows are added together. Other states: Medicare and Medicaid spending on GLP-1 drugs.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.